Results 11 to 20 of about 14,264 (186)

Increasing the production of insulin glargine in Pichia pastoris through medium modification [PDF]

BIO Web of Conferences
Insulin is the primary drug for managing diabetes mellitus, especially for individuals with type 1 diabetes mellitus. Producing insulin glargine, a long-acting insulin analogue, using Pichia pastoris is a notable advancement in biopharmaceutical ...
Hardianto Dudi, Safarrida Anna, Prayoga Gilang Surya, Ananda Zr Yufva Pramudia, Munirah, Martius Efrida, Royani Juwartina Ida, Hartuti Endah Dwi   +7 more
doaj   +2 more sources

Insulin glargine 300 U/ml in the management of diabetes: clinical utility and patient perspectives [PDF]

Patient Preference and Adherence, 2016
Bastiaan E de Galan Department of Internal Medicine, Radboud University Medical Center, Nijmegen, the Netherlands Abstract: There is ongoing interest in optimizing basal insulin treatment by developing insulins with a flat pharmacological profile, a ...
de Galan BE
doaj   +3 more sources

Efficacy and Safety of Once-Weekly Semaglutide 2.0 mg as an Add-On to Dose-Reduced Insulin Glargine versus Dose-Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE). [PDF]

Diabetes Obes Metab
ABSTRACT Aims Type 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and ...
Rodbard HW, Irace C, Lobo J, Makrilakis K, Priyadarshini P, Sivalingam S, Povedano ST, Bhargava A.   +7 more
europepmc   +2 more sources

Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials. [PDF]

Diabetes Obes Metab
ABSTRACT Aims This post hoc analysis of COMBINE 1–3 assessed efficacy and hypoglycaemia outcomes with IcoSema (once‐weekly combination therapy of basal insulin icodec and semaglutide [a glucagon‐like peptide‐1 analogue]) versus comparators in adults with type 2 diabetes (T2D) by kidney and liver function subgroups.
Ji L, Andersen JD, Benamar M, Ponzani P, Unnikrishnan AG, Vinther S, Rea R.   +6 more
europepmc   +2 more sources

Analysis of Suffix Use for Biosimilar Product Identification in Postmarketing Adverse Event Reporting. [PDF]

Clin Pharmacol Ther
Accurate identification of medicines used in adverse event reports is crucial for effective postmarketing safety surveillance. The US Food and Drug Administration's (FDA) four‐letter suffix naming convention was designed to facilitate accurate biological product identification, but the extent to which these suffixes have been incorporated into ...
Stojanovic D, Wolf L, Ricci MS, Muñoz MA.   +3 more
europepmc   +2 more sources

Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled Type 2 diabetes in the United Kingdom

Cardiovascular Diabetology, 2008
Objective Exenatide belongs to a new therapeutic class in the treatment of diabetes (incretin mimetics), allowing glucose-dependent glycaemic control in Type 2 diabetes.
Tetlow Anthony P, Evans Mark, Woehl Anette, McEwan Philip   +3 more
doaj   +1 more source

Clinical and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes [PDF]

, 2004
Objectives: To assess the clinical and cost-effectiveness of continuous subcutaneous insulin infusion (CSII) compared with multiple daily injections (MDI) in the delivery of intensive insulin therapy for the treatment of diabetes mellitus.
Green, C., N Waugh, Waugh, Norman, M Sidhu, D Hartwell, Colquitt, J. L. (Jill L.), Hartwell, D. (Debbie L.), C Green, J Colquitt, Sidhu, M. K.   +9 more
core   +1 more source

The Role of Insulin Glargine and Human Insulin in the Regulation of Thyroid Proliferation Through Mitogenic Signaling

Frontiers in Endocrinology, 2019
Our aim was to investigate whether human insulin (HI) or insulin glargine treatment could promote the proliferation of thyroid cells and determine the association between type 2 diabetes and thyroid disease.
Xiaoli Sheng, Kannan Yao, Anwen Shao, Sheng Tu, Xinxia Zhang, Ting Chen, Dingguo Yao   +6 more
doaj   +1 more source

Efficacy and Safety of iGlarLixi Versus IDegAsp by Baseline Age, Disease Duration and HbA1c in Chinese People With Type 2 Diabetes: Post Hoc Analyses of the Soli-D Study. [PDF]

Diabetes Obes Metab
ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Zhang S, Gu Y, Cheng Y, Hu Y, Li B, Alvarez A, Lauand F, Melas-Melt L, Zhang M, Jiang Y, Du Q, Kang L, Mu Y, Gu W, Kuang H.   +14 more
europepmc   +2 more sources

Remission of tuberculosis following control of glycemic excursions in a patient with type 2 diabetes mellitus: A case report

Journal of Diabetology, 2022
Rationale: Tuberculosis (TB) and diabetes mellitus (DM) are converging epidemics, each worsening the morbidity of the other. Chronic hyperglycemia is associated with dysfunctional immunity to Mycobacterium in patients with DM and, therefore, is likely to
Anand Hinduja
doaj   +1 more source